NCT06955741View on ClinicalTrials.gov

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

September 11, 2025

Study Completion Date

September 11, 2025

Conditions
Healthy Volunteer
Interventions
DRUG

BMS-986446 IV

Specified dose on specified days was administered intravenously (IV).

DRUG

BMS-986446 SC

Specified dose on specified days was administered subcutaneously (SC).

DRUG

Acetaminophen

Specified dose on specified days

DRUG

Loratadine

Specified dose on specified days

Trial Locations (2)

92801

Local Institution - 0001, Anaheim

Local Institution - 10000, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06955741 - A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants | Biotech Hunter | Biotech Hunter